DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
SOBLIDOTIN
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Lung Neoplasms; Sarcoma
Unknown
SOBLIDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
DQC51A0WQH
Molecule Type:
Small molecule
Molecular Formula:
C39H67N5O6
Molecular Weight:
701.99
AlogP:
3.99
PSA:
120.52
HBD:
2.0
HBA:
#RotB:
20.0
Source:
GREMUBAMAB
2
Antibody
Investigational
Unknown
Unknown
Pneumonia
Low calcium response locus protein V inhibitor
GREMUBAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
3QG7W0YN2Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IPH-2101
2
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Multiple Myeloma
Killer cell immunoglobulin-like receptor 2DL1 inhibitor
IPH-2101
×
Maximum Phase:
2
First Approval:
None
UNII:
5Q686XLG8L
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BEMARITUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Adenocarcinoma
Unknown
BEMARITUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
RJW23BQ0KW
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OZORALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
TNF-alpha inhibitor
OZORALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
05ZCK72TXZ
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EVODENOSON
2
Small molecule
Investigational
Unknown
Unknown
Glaucoma, Open-Angle; Ocular Hypertension
Adenosine A2a receptor agonist
EVODENOSON
×
Maximum Phase:
2
First Approval:
None
UNII:
HZ03U10J2Z
Molecule Type:
Small molecule
Molecular Formula:
C23H29N7O6
Molecular Weight:
499.53
AlogP:
-0.47
PSA:
177.95
HBD:
4.0
HBA:
#RotB:
4.0
Source:
DEFACTINIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Mesothelioma; Ovarian Neoplasms
Focal adhesion kinase 1 inhibitor
DEFACTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
53O87HA2QU
Molecule Type:
Small molecule
Molecular Formula:
C20H21F3N8O3S
Molecular Weight:
510.5
AlogP:
2.4
PSA:
142.1
HBD:
3.0
HBA:
#RotB:
8.0
Source:
PF-06291874
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Glucagon receptor antagonist
PF-06291874
×
Maximum Phase:
2
First Approval:
None
UNII:
CGY4I8F278
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NBI-921352
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
NBI-921352
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C22H25FN4O2S2
Molecular Weight:
460.6
AlogP:
4.1
PSA:
65.54
HBD:
1.0
HBA:
#RotB:
7.0
Source:
LACTOBACILLUS RHAMNOSUS
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
LACTOBACILLUS RHAMNOSUS
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AR9281
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Epoxide hydratase inhibitor
AR9281
×
Maximum Phase:
2
First Approval:
None
UNII:
4HA03Q8EZ9
Molecule Type:
Small molecule
Molecular Formula:
C18H29N3O2
Molecular Weight:
319.45
AlogP:
2.27
PSA:
61.44
HBD:
2.0
HBA:
#RotB:
2.0
Source:
PIBOSEROD
2
Small molecule
Investigational
Unknown
Unknown
Atrial Fibrillation; Heart Failure
Serotonin 4 (5-HT4) receptor antagonist
PIBOSEROD
×
Maximum Phase:
2
First Approval:
None
UNII:
4UQ3S81B25
Molecule Type:
Small molecule
Molecular Formula:
C22H31N3O2
Molecular Weight:
369.51
AlogP:
3.67
PSA:
46.5
HBD:
1.0
HBA:
#RotB:
6.0
Source:
PF-00217830
2
Small molecule
Investigational
Unknown
Unknown
Schizophrenia
Dopamine D2 receptor partial agonist
PF-00217830
×
Maximum Phase:
2
First Approval:
None
UNII:
8BC08N1MS5
Molecule Type:
Small molecule
Molecular Formula:
C26H30N4O2
Molecular Weight:
430.55
AlogP:
4.1
PSA:
57.7
HBD:
1.0
HBA:
#RotB:
7.0
Source:
AUY922
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
AUY922
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NAFITHROMYCIN
2
Small molecule
Investigational
Unknown
Unknown
Pneumonia, Bacterial
Unknown
NAFITHROMYCIN
×
Maximum Phase:
2
First Approval:
None
UNII:
75F74Y2R70
Molecule Type:
Small molecule
Molecular Formula:
C42H62N6O11S
Molecular Weight:
859.06
AlogP:
4.12
PSA:
224.18
HBD:
2.0
HBA:
#RotB:
10.0
Source:
NAMODENOSON
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C, Chronic; Carcinoma, Hepatocellular; Non-alcoholic Fatty Liver Disease
Adenosine A3 receptor agonist
NAMODENOSON
×
Maximum Phase:
2
First Approval:
None
UNII:
Z07JR07J6C
Molecule Type:
Small molecule
Molecular Formula:
C18H18ClIN6O4
Molecular Weight:
544.74
AlogP:
1.06
PSA:
134.42
HBD:
4.0
HBA:
#RotB:
5.0
Source:
OMBURTAMAB
2
Antibody
Investigational
Unknown
Unknown
Medulloblastoma; Meningeal Carcinomatosis
Unknown
OMBURTAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
XQL6783S5T
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BLOSOZUMAB
2
Antibody
Investigational
Unknown
Unknown
Osteoporosis, Postmenopausal; Osteoporosis
Sclerostin inhibitor
BLOSOZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
83YOM0NEL5
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELISMETREP
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Neuropathies; Hot Flashes
Transient receptor potential cation channel subfamily M member 8 inhibitor
ELISMETREP
×
Maximum Phase:
2
First Approval:
None
UNII:
KIB8V5UR7D
Molecule Type:
Small molecule
Molecular Formula:
C27H21F3N2O5S
Molecular Weight:
542.53
AlogP:
6.1
PSA:
96.8
HBD:
1.0
HBA:
#RotB:
8.0
Source:
PLN-74809
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
PLN-74809
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UBENIMEX
2
Small molecule
Investigational
Unknown
Unknown
Hypertension, Pulmonary; Lymphedema
Unknown
UBENIMEX
×
Maximum Phase:
2
First Approval:
None
UNII:
I0J33N5627
Molecule Type:
Small molecule
Molecular Formula:
C16H24N2O4
Molecular Weight:
308.38
AlogP:
0.53
PSA:
112.65
HBD:
4.0
HBA:
#RotB:
8.0
Source:
FIRTECAN PEGOL
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma; Neoplasms; Breast Neoplasms
Unknown
FIRTECAN PEGOL
×
Maximum Phase:
2
First Approval:
None
UNII:
WC4978T687
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GATAPARSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Leukemia, Myeloid, Acute; Prostatic Neoplasms, Castration-Resistant
Unknown
GATAPARSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
895O8QKF18
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BI-505
2
Antibody
Investigational
Unknown
Unknown
Multiple Myeloma
Intercellular adhesion molecule-1 antagonist
BI-505
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MGB-BP-3
2
Small molecule
Investigational
Unknown
Unknown
Clostridium Infections
DNA binding agent
MGB-BP-3
×
Maximum Phase:
2
First Approval:
None
UNII:
532PWU9738
Molecule Type:
Small molecule
Molecular Formula:
C36H37N7O4
Molecular Weight:
631.74
AlogP:
4.65
PSA:
122.52
HBD:
3.0
HBA:
#RotB:
10.0
Source:
TALAROZOLE
2
Small molecule
Investigational
Unknown
Unknown
Inflammation; Acne Vulgaris; Psoriasis
Cytochrome P450 26A1 inhibitor
TALAROZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
XKD9N5CJ6W
Molecule Type:
Small molecule
Molecular Formula:
C21H23N5S
Molecular Weight:
377.52
AlogP:
5.66
PSA:
55.63
HBD:
1.0
HBA:
#RotB:
7.0
Source:
AVE-1642
2
Antibody
Investigational
Unknown
Unknown
Liver Neoplasms; Multiple Myeloma; Breast Neoplasms
Insulin-like growth factor I receptor antagonist
AVE-1642
×
Maximum Phase:
2
First Approval:
None
UNII:
Z9U2SS9ZC8
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GALICAFTOR
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis
Cystic fibrosis transmembrane conductance regulator positive modulator
GALICAFTOR
×
Maximum Phase:
2
First Approval:
None
UNII:
J0IIT8QSQS
Molecule Type:
Small molecule
Molecular Formula:
C28H21F4NO7
Molecular Weight:
559.47
AlogP:
5.72
PSA:
103.32
HBD:
2.0
HBA:
#RotB:
7.0
Source:
BREQUINAR
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Severe Acute Respiratory Syndrome
Unknown
BREQUINAR
×
Maximum Phase:
2
First Approval:
None
UNII:
5XL19F49H6
Molecule Type:
Small molecule
Molecular Formula:
C23H15F2NO2
Molecular Weight:
375.37
AlogP:
5.85
PSA:
50.19
HBD:
1.0
HBA:
#RotB:
3.0
Source:
TOL-101
2
Antibody
Investigational
Unknown
Unknown
Renal Insufficiency, Chronic
T-cell receptor inhibitor
TOL-101
×
Maximum Phase:
2
First Approval:
None
UNII:
28X0AGG6P8
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
L-THREONIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity
Unknown
L-THREONIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
75B0PMW2JF
Molecule Type:
Small molecule
Molecular Formula:
C4H8O5
Molecular Weight:
136.1
AlogP:
-2.21
PSA:
97.99
HBD:
4.0
HBA:
#RotB:
3.0
Source:
ILODECAKIN
2
Protein
Investigational
Unknown
Unknown
Cicatrix
Unknown
ILODECAKIN
×
Maximum Phase:
2
First Approval:
None
UNII:
6GY6UY4UR7
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FB825
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
FB825
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VX-787
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
VX-787
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MK-0941
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Hexokinase type IV activator
MK-0941
×
Maximum Phase:
2
First Approval:
None
UNII:
YZ1L3KR377
Molecule Type:
Small molecule
Molecular Formula:
C22H28N4O9S2
Molecular Weight:
556.62
AlogP:
2.41
PSA:
132.64
HBD:
2.0
HBA:
#RotB:
9.0
Source:
1
2
…
179
180
181
182
183
184
185
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA